These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26767009)

  • 21. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
    Sakairi Y; Nakajima T; Yasufuku K; Ikebe D; Kageyama H; Soda M; Takeuchi K; Itami M; Iizasa T; Yoshino I; Mano H; Kimura H
    Clin Cancer Res; 2010 Oct; 16(20):4938-45. PubMed ID: 20926401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
    Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
    Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
    Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
    Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
    Xu CW; Wang G; Wang WL; Gao WB; Han CJ; Gao JS; Zhang LY; Li Y; Wang L; Zhang YP; Tian YW; Qi DD
    Exp Ther Med; 2015 Jun; 9(6):2151-2154. PubMed ID: 26136951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer.
    Tan S; Sun D; Pu W; Gou Q; Guo C; Gong Y; Li J; Wei YQ; Liu L; Zhao Y; Peng Y
    Mol Cancer; 2018 Sep; 17(1):138. PubMed ID: 30236141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.
    Sanders HR; Li HR; Bruey JM; Scheerle JA; Meloni-Ehrig AM; Kelly JC; Novick C; Albitar M
    Cancer Genet; 2011 Jan; 204(1):45-52. PubMed ID: 21356191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.
    Wang Y; Wang S; Xu S; Qu J; Liu B
    PLoS One; 2014; 9(10):e110617. PubMed ID: 25360721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
    Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
    Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
    Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological and Prognostic Significance of
    Shi J; Gu W; Zhao Y; Zhu J; Jiang G; Bao M; Shi J
    Cancer Manag Res; 2020; 12():589-598. PubMed ID: 32158263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.
    Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
    Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
    Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.
    Liu L; Zhan P; Zhou X; Song Y; Zhou X; Yu L; Wang J
    PLoS One; 2015; 10(3):e0117032. PubMed ID: 25785456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant mutation status of
    Li J; Zhang B; Zhang Y; Xu F; Zhang Z; Shao L; Yan C; Ulivi P; Denis MG; Christopoulos P; Thomas de Montpréville V; Bernicker EH; van der Wekken AJ; Wang C; Yue D
    Transl Lung Cancer Res; 2021 Mar; 10(3):1525-1535. PubMed ID: 33889527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
    Xu X; Liu D; Wen J; Chen J; Fan M
    Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
    Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
    Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
    Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
    J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.